Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders – Business Wire

Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders – Business Wire
Source: Google NewsPublished on 2021-02-17